ALLONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Allogene Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$1.30−0.01 (-0.76%)
Close on Oct 19, 2026
- Market cap
- $427.61M
- P/E (TTM)
- –
- Dividend yield
- 0.00%
Share price
+$0.07 (+5.69%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Allogene Therapeutics, Inc. saw revenue fall 100.0% to $0 over fiscal 2025. Free cash flow was -$102.60M.
Revenue
$0
-100.0% vs. a year earlier
Operating income
-$180.32M
TTM Q2 2026
Free cash flow
-$102.60M
TTM Q2 2026
EPS, diluted
-$0.67
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Jun 30, 2026
Valuation
- Market cap
- $427.61M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 0.98
- Dividend yield
- 0.00%
- Free cash flow yield
- -23.99%
Fundamentals
- Revenue
- $0
- Net income
- -$165.49M
- EPS, diluted
- -$0.67
- Free cash flow
- -$102.60M
- Book value per share
- $1.33
- Diluted shares
- 329M
Nine years at a glance
Fiscal years 2017 to 2025 and trailing twelve months, USD
Revenue
–
Operating income
-$180.32M
Net income
-$165.49M
EPS, diluted
-$0.67
Free cash flow
-$102.60M
Reported periodTrailing twelve months